Biopharma in Saudi Vision 2030 & Oman Vision 2040
Saudi Vision 2030 & Oman Vision 2040 in Biotech (Biopharma Focus) What sets Saudi Arabia’s biotech vision under Vision 2030 apart from Oman’s? Saudi Arabia aims to become a regional and global biotech hub, anchored by a National Biotechnology Strategy (NBS) that localizes vaccine production and biopharmaceuticals, advances genomics/gene therapy, and strengthens agri-biotechnology. Core pillars […]
Impact of Biopharma in MENA
What role do biopharma companies play in the MENA healthcare landscape? Biopharma companies are not just players, but catalysts of transformation in the MENA healthcare landscape. They introduce advanced diagnostics and therapies, and upgrade systems that deliver care, ushering in a new era of healthcare. Primary contributions Introduction of biologics and advanced therapies Strengthening clinical […]
Packaging the Future of Biosimilars: An Adalimumab Biosimilar Journey
What makes Adalimumab such a critical medicine? Biologics, particularly Adalimumab, have significantly advanced the treatment of chronic and autoimmune diseases. Adalimumab, a widely prescribed therapy for conditions like rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis, has been a standout in this revolution. However, the innovation in biologics, such as Adalimumab, comes with a hefty […]
The Future of Cancer Cures: Stories of Science and Hope
What does it mean to “cure” cancer? Cancer is not a single disease, but rather an umbrella term for more than 200 distinct conditions. A universal cure is unlikely, because cancers differ not only by type but also by patient, stage, and genetic profile. Instead, medicine aims at multiple cures, targeted strategies, and long-term disease […]
Monoclonal Antibodies & Biologics: The Next Era with Biosimilars
Biologics have reshaped modern medicine, offering targeted and highly effective therapies for diseases once considered intractable. Among them, monoclonal antibodies (mAbs) stand at the forefront. These laboratory-engineered proteins, capable of recognizing specific antigens, have not only revolutionized fields like oncology, rheumatology, gastroenterology, and dermatology but have also become the world’s highest-earning medicines. Yet with […]
The Society & The Necessity for Biosimilars
Biosimilars: Science, Need, and the Role of Governments in Shaping Access Over the last two decades, biologic medicines have revolutionized the treatment of autoimmune disorders, cancers, and rare diseases. These therapies, produced through living systems, have often been life-changing but also come with staggering costs. The global expansion of biologics has highlighted both a […]
The Age of Adalimumab and Real-World Outcomes
The Adalimumab Era, Reimagined: Interchangeability, Real-World Outcomes, and Access in the Biosimilar Age Adalimumab, a fully human monoclonal antibody targeting tumor necrosis factor-α (TNF-α), has transformed the management of immune-mediated inflammatory diseases across rheumatology, dermatology, gastroenterology, and ophthalmology. As its market exclusivity has waned, a diverse ecosystem of adalimumab biosimilars has emerged, accompanied by regulatory […]
Biopharma Investment Pathways and Strategic Gaps in the GCC
The Future of Biopharma in the GCC: Investment Pathways and Strategic Gaps The Gulf Cooperation Council (GCC) is entering a transformative phase in biotechnology and biopharmaceuticals. No longer content with importing drugs and vaccines, member states are actively investing in cutting-edge platforms ranging from biologics manufacturing to AI-driven drug discovery. This shift reflects broader […]
Antigen Loss Following CAR-T Cell Therapy: Mechanisms, Implications, and Potential Solutions
Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the landscape of cancer treatment, particularly in hematological malignancies like leukemia and lymphoma. However, despite its groundbreaking success, the emergence of antigen loss in approximately 30% to 70% of patients treated with CAR-T therapy remains a significant clinical challenge. Antigen loss refers to the loss or reduction […]
Biosimilars in Healthcare Economics: Enhancing Global Access to Medicine
Biosimilars in Healthcare Economics: Enhancing Global Access to Medicine Date: July 2025 Healthcare systems globally are facing unprecedented economic pressure due to the soaring costs of biologic therapies. Biologic medicines have significantly improved patient outcomes across various chronic and severe conditions, yet their high costs pose substantial barriers, limiting equitable healthcare access worldwide. The […]
